“Unlike antibody-based vaccines, T-cell-based vaccines kill the infected cell, preventing virus replication, and could provide long-term memory to recipients,” he said.
Biovac CEO Dr Morena Makhoana said the collaboration was a strategic step in the quest to build vaccine-manufacturing capability in Africa.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: